SCHEMBL5578095

SCHEMBL5578095

C=CCc1nc(-c2n[nH]cc2NC(=O)c2c(F)cccc2F)[nH]c1-c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.40
MEN1 O00255 6/20 0.38
KMT2A Q03164 6/20 0.38
EGFR P00533 2/20 0.38
AURKB Q96GD4 2/20 0.38
DYRK3 O43781 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
ABL1 P00519 1/20 0.38
NTRK1 P04629 1/20 0.38
PRKCG P05129 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
CDK1 P06493 1/20 0.38
FES P07332 1/20 0.38
CSF1R P07333 1/20 0.38
LYN P07948 1/20 0.38
ROS1 P08922 1/20 0.38
KIT P10721 1/20 0.38
PIM1 P11309 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5578102 0.85 MAPT (0.40) MAPTMEN1KMT2AEGFRAURKB
SCHEMBL5578169 0.85 KMT2A (0.46) MAPTMEN1KMT2AEGFRAURKB
SCHEMBL5578476 0.83 KMT2A (0.47) MAPTMEN1KMT2AEGFRAURKB
SCHEMBL5578149 0.81 CDK2 (0.39) MAPTMEN1KMT2AEGFRAURKB
SCHEMBL5578064 0.78 ADORA3 (0.39) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL5578190 0.78 CDK1 (0.36) MAPTMEN1KMT2AEGFRAURKB
SCHEMBL5578455 0.77 CDK2 (0.37) MAPTMEN1KMT2AEGFRAURKB
SCHEMBL14511697 0.77 MAPT (0.38) MAPTAURKBCDK1CDK2POLB
SCHEMBL1646494 0.76 MAPT (0.60) MAPTMEN1KMT2AAURKBCDK1
SCHEMBL5578150 0.76 CDK1 (0.45) MAPTMEN1KMT2AEGFRAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070105900-A1 Pharmaceutical compounds ATEX THERAPEUTICS, LIMITED (GB) 2007-05-10 US disclosed
US-20070105900-A1 Pharmaceutical compounds ATEX THERAPEUTICS, LIMITED (GB) 2007-05-10 US disclosed
US-20070105900-A1 Pharmaceutical compounds ATEX THERAPEUTICS, LIMITED (GB) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105900-A1 Pharmaceutical compounds AURKA, AURKC, CDK1 MAPT 1133/4885MEN1 1585/4885KMT2A 1706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.